Lexaria Bioscience Corp. (LEXX) Revenue History
Annual and quarterly revenue from 2006 to present
LEXX Revenue Over Time (2006–2025)
LEXX Revenue Growth History
11 of 19 years with positive growth- FY2006 revenue growth
- N/A
- FY2007 revenue growth
- +1146.6%
- FY2008 revenue growth
- +255.8%
- FY2009 revenue growth
- -53.2%
- FY2010 revenue growth
- -14.1%
- FY2011 revenue growth
- +212.8%
- FY2012 revenue growth
- +19.8%
- FY2013 revenue growth
- -19.2%
- FY2014 revenue growth
- +0.0%
- FY2015 revenue growth
- -98.7%
- FY2016 revenue growth
- +177.0%
- FY2017 revenue growth
- +56.3%
- FY2018 revenue growth
- +580.9%
- FY2019 revenue growth
- -48.6%
- FY2020 revenue growth
- +41.4%
- FY2021 revenue growth
- +129.6%
- FY2022 revenue growth
- -64.7%
- FY2023 revenue growth
- -11.4%
- FY2024 revenue growth
- +105.2%
- FY2025 revenue growth
- +52.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | -100.0% |
| Q4 2025 | $174K | +107.1% |
| Q3 2025 | $174K | +107.1% |
| Q2 2025 | $174K | +20.0% |
| Q1 2025 | $184K | +21.6% |
| Q4 2024 | $84K | +173.3% |
| Q3 2024 | $84K | +8.1% |
| Q2 2024 | $145K | +624.1% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
LEXX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
LEXX Revenue Analysis (2006–2025)
Current Revenue & Growth
As of June 23, 2026, Lexaria Bioscience Corp. (LEXX) generated trailing twelve-month (TTM) revenue of $522,000, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Historical Growth Trajectory
LEXX's 5-year compound annual growth rate (CAGR) stands at +17.5%, indicating consistent double-digit revenue growth. The 3-year CAGR of +40.3% exceeds the 5-year average, indicating an acceleration in the most recent period. Lexaria Bioscience Corp.'s highest annual revenue of $1.4 million was recorded in 2012.
Revenue by Segment
LEXX's revenue is primarily driven by IP Licensing (99%), and B2B (1%). With over half of revenue concentrated in IP Licensing, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ATAI (+87.2% YoY), and NRXP — LEXX has underperformed the peer group in revenue growth. Compare LEXX vs ATAI →
LEXX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LEXXCurrent | $522,000 | -100.0% | +17.5% | -1648.0% | |
 ATAI | $4M | +87.2% | - | -2439.7% | |
 NRXP | $1M | - | - | -1324.4% |
LEXX Historical Revenue Data (2006–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $706K | +52.0% | $587K | 83.2% | $-11,633,373 | -1648.0% |
| 2024 | $464K | +105.2% | $383K | 82.6% | $-5,695,294 | -1226.7% |
| 2023 | $226K | -11.4% | $54K | 23.9% | $-6,534,022 | -2888.5% |
| 2022 | $255K | -64.7% | $47K | 18.3% | $-6,500,844 | -2545.4% |
| 2021 | $723K | +129.6% | $547K | 75.7% | $-5,520,597 | -763.8% |
| 2020 | $315K | +41.4% | $69K | 22.0% | $-4,128,904 | -1311.6% |
| 2019 | $223K | -48.6% | $-194,032 | -87.2% | $-4,141,979 | -1860.6% |
| 2018 | $433K | +580.9% | $406K | 93.7% | $-6,613,185 | -1526.3% |
| 2017 | $64K | +56.3% | $32K | 50.9% | $-1,923,450 | -3022.4% |
| 2016 | $41K | +177.0% | $-5,516 | -13.5% | $-1,259,617 | -3093.5% |
| 2015 | $15K | -98.7% | $-15,181 | -103.3% | $-1,928,212 | -13115.3% |
| 2014 | $1.1M | +0.0% | $302K | 27.5% | $294K | 26.8% |
| 2013 | $1.1M | -19.2% | $302K | 27.5% | $-56,901 | -5.2% |
| 2012 | $1.4M | +19.8% | $574K | 42.3% | $-13,867 | -1.0% |
| 2011 | $1.1M | +212.8% | $465K | 41.1% | $-259,500 | -22.9% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LEXX — Frequently Asked Questions
Quick answers to the most common questions about buying LEXX stock.
Is LEXX's revenue growth accelerating or slowing?
LEXX revenue is declining -100.0% year-over-year. TTM revenue fell to $522000.00, contrasting with the 5-year CAGR of +17.5%. The reversal reflects either macro headwinds or company-specific challenges.
What is LEXX's revenue history from 2006 to 2026?
Lexaria Bioscience Corp. (LEXX) revenue history spans 2006 to 2026. TTM revenue as of 2026 is $522000.00, growing at -100.0% YoY. The 5-year CAGR is +17.5%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is LEXX's long-term revenue growth rate (CAGR)?
Lexaria Bioscience Corp.'s 5-year revenue CAGR of +17.5% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for LEXX.
Why does LEXX's quarterly revenue fluctuate?
LEXX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Lexaria Bioscience Corp.'s revenue data from 2006 to 2026 shows full historical quarterly detail on this page.
How is LEXX's revenue distributed by segment?
LEXX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does LEXX's revenue compare to industry peers?
Lexaria Bioscience Corp. (LEXX) with TTM revenue of $522000.00 and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.